Post-Stroke Facial Rehabilitation — Procedure Guide, Recovery & Risks | MyMedicPlus

Post-stroke facial weakness (central facial palsy) results from damage to the corticobulbar tracts connecting the motor cortex to the facial nerve nucleus in the brainstem. Unlike peripheral facial nerve palsy (Bell's palsy), central facial palsy from stroke predominantly affects the lower face contralateral to the lesion, while the forehead is relatively spared due to bilateral cortical representation. Approximately 60–75% of stroke survivors experience some degree of facial weakness, and for many, it affects communication, eating, drinking, and psychosocial wellbeing. Post-stroke facial rehabilitation is a multimodal programme delivered by specialist speech-language pathologists, physiotherapists, and occupational therapists. Techniques include neuromuscular retraining, mirror therapy, biofeedback, and facial exercises designed to exploit neuroplasticity and drive cortical reorganisation in the recovery period. Post-stroke facial palsy results from ischaemic or haemorrhagic stroke affecting the facial motor cortex, corticobulbar tracts, or facial nerve nucleus in the pons, causing unilateral lower face weakness (central facial palsy) or, less commonly, total ipsilateral facial paralysis. Unlike peripheral facial palsy (Bell's palsy), central post-stroke facial palsy characteristically spares the forehead (due to bilateral cortical representation of forehead muscles) and presents with flattened nasolabial fold, drooping mouth corner, and difficulty with voluntary facial expressions. Facial rehabilitation after stroke encompasses neuromuscular re-education, facial exercises, electrostimulation, mirror therapy, and in some centres botulinum toxin injection to reduce spasticity on the contralateral intact side when synkinesis develops. Outcomes depend on stroke type, severity, rehabilitation initiation timing, and intensity of therapy. Recovery of central facial palsy can be partial or complete, particularly when rehabilitation begins early.

Post-stroke facial rehabilitation is indicated for all stroke survivors with clinically significant facial weakness affecting function (eating, drinking, speech, oral hygiene) or psychosocial quality of life. Therapy is most effective when initiated early — within the first 2–4 weeks of stroke onset — when neuroplasticity is at its peak, though meaningful improvement can occur up to 2 years post-stroke with intensive rehabilitation. Patients with oral dysphagia related to facial and oropharyngeal weakness require concurrent swallowing rehabilitation under a speech-language pathologist. Botulinum toxin A injection is specifically indicated for post-stroke synkinesis — involuntary co-contraction of facial muscles (e.g., eye closure when attempting to smile) — that typically develops 3–6 months post-stroke in patients with partial recovery. Facial rehabilitation is also appropriate for patients with facial weakness from other acquired brain injuries, brainstem tumours, or Bell's palsy.

Facial rehabilitation begins with a structured assessment of facial movement using standardised tools such as the Sunnybrook Facial Grading System or the House-Brackmann scale. Treatment is individualised based on the pattern and degree of weakness. Neuromuscular retraining uses specific facial exercises performed in front of a mirror, with the therapist guiding small, precise movements targeting individual muscle groups — frowning, lip pursing, cheek inflation, eye closure — progressing from passive assisted movement to active movement as strength returns. Mirror therapy positions a mirror at the midline so the unaffected side provides a reflected image of normal movement, retraining the motor cortex through visual feedback. Electromyographic (EMG) biofeedback uses surface electrodes to display muscle activity, helping patients learn to isolate target muscles. For synkinesis, botulinum toxin type A (onabotulinumtoxinA, abobotulinumtoxinA) is injected at low doses (5–20 units per site) into overactive muscles using EMG or electrical stimulation guidance, reducing abnormal co-contraction and improving voluntary movement. Low-level laser therapy and transcutaneous electrical stimulation are used as adjuncts in some rehabilitation centres. Neuromuscular re-education uses biofeedback techniques — mirror therapy and electromyographic (EMG) biofeedback — to enable patients to observe and consciously control facial muscle activation. Specific facial exercises target individual muscle groups: orbicularis oculi (eye closure), orbicularis oris (lip closure), zygomaticus major (smiling), and buccinator (cheek movement). Electrical stimulation of facial muscles (functional electrical stimulation, FES) may supplement active exercise in patients with complete paralysis. Botulinum toxin injection to the contralateral normal side is used selectively to reduce asymmetry and treat hyperkinesis. Acupuncture has been studied as adjunctive therapy in Asian countries, with moderate evidence for improvement. Speech therapy addresses dysarthria and dysphagia co-occurring with facial motor deficits. A structured graded exercise programme follows the Sunnaas Face Scale or Facial Disability Index for monitoring.

Early intensive facial rehabilitation significantly improves facial function compared with no treatment: systematic review evidence shows Sunnybrook scores improving by 15–25 points with neuromuscular retraining protocols in the first 3–6 months post-stroke. Mirror therapy combined with neuromuscular retraining produces superior outcomes to either alone. Botulinum toxin injection for post-stroke synkinesis achieves meaningful functional improvement in 70–80% of treated patients, with effects lasting 3–4 months and treatment repeated as required. Patients who undergo intensive rehabilitation within the first month achieve better long-term outcomes: 60–70% of patients with moderate initial facial weakness regain near-normal or normal facial symmetry at rest by 6 months, though dynamic movement often shows residual asymmetry. Facial rehabilitation initiated within 2–4 weeks of stroke onset is associated with significantly better outcomes than late-started therapy. Mirror therapy and EMG biofeedback improve symmetry and voluntary control in controlled trials. Improvement in facial function correlates with improved psychosocial outcomes — reduced depression, social isolation, and communication difficulties. Botulinum toxin treatment for hyperkinesis achieves functional improvement lasting 3–4 months per injection cycle. Acupuncture may provide adjunctive benefit in improving muscle tone and nerve regeneration signals in selected patients.

Facial rehabilitation exercises carry minimal physical risk. Excessive or incorrectly performed exercises without therapist supervision can reinforce compensatory patterns and worsen synkinesis; this underscores the importance of specialist-guided therapy over self-directed exercises alone. Botulinum toxin injections for synkinesis carry a small risk of spread to adjacent muscles — causing transient excessive weakness, ptosis, or asymmetric smile — typically lasting 4–8 weeks as the toxin effect wears off. Very rarely, generalised weakness from toxin spread has been reported with high doses. Emotional and psychological distress from facial disfigurement, communication difficulties, and social withdrawal are significant and often underaddressed consequences of facial palsy after stroke; psychological support and social reintegration programmes should be integrated into rehabilitation. Facial rehabilitation exercises carry minimal physical risk but require sustained patient motivation and consistent practice to maintain gains. Incorrect exercise technique may reinforce synkinesis or abnormal muscle co-contraction patterns. Electrical stimulation used at inappropriate parameters may cause discomfort or paradoxical muscle overactivation. Botulinum toxin injection risks (bruising, temporary overcorrection, spread to unintended muscles causing ptosis or asymmetry) apply as for other facial botulinum toxin uses. Over-exercise of hyperkinetic muscles may worsen facial spasm.

Facial rehabilitation begins in the acute stroke unit within 24–72 hours of admission. Initial sessions focus on maintaining oral hygiene, preventing contracture, and passive range-of-motion exercises. On transfer to a rehabilitation ward or community stroke service, therapy intensifies to 30–60 minutes daily, 5 days per week. Home exercise programmes — individualised exercises performed for 10–15 minutes, 2–3 times daily — extend therapy between supervised sessions. Progress is formally reassessed at 6-weekly intervals using standardised grading tools. Most recovery of facial movement occurs in the first 3 months, with slower gains continuing for 12–24 months. Botulinum toxin injections for synkinesis are repeated every 3–4 months as needed. Long-term support from a specialist facial palsy service addresses late complications — synkinesis, facial contracture, eye protection — beyond the acute and subacute rehabilitation phases.